Skip to search formSkip to main contentSkip to account menu

cetrorelix

Known as: cetrorelix [Chemical/Ingredient], Cetrorelixum, LHRH, N-Ac-1-Nal(2)-2-Phe(pCl)-3-Pal(3)-6-Cit-10-Ala- 
Cetrorelix is a synthetic decapeptide which is structurally related to gonadotrophin-releasing hormone (luteinising-hormone releasing hormone). It… 
National Institutes of Health

Related topics

Related topics

14 relations
Cetrorelix acetateChorionic GonadotropinDrug AllergyMannitol

Narrower (4)

CetrotideD-20761SB 75cetrorelix pamoate

Broader (3)

Fertility Agents, FemaleGonadorelinHormone Antagonists

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor.
BACKGROUND The majority of human endometrial and ovarian cancer cell lines express receptors for GnRH. Their proliferation is… 
Highly Cited
2001
Highly Cited
2001
Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
Luteinizing hormone (LH) is mandatory for the maintenance of the corpus luteum. Ovarian stimulation for IVF has been associated… 
2000
2000
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro.
2000
2000
Pharmacokinetic‐Pharmacodynamic Modeling of Testosterone and Luteinizing Hormone Suppression by Cetrorelix in Healthy Volunteers
Cetrorelix (CET), a potent luteinizing hormone‐releasing hormone (LH‐RH) antagonist, was recently approved for the prevention of… 
1997
1997
Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions.
Highly Cited
1996
Highly Cited
1996
Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).
A third generation gonadotrophin-releasing hormone antagonist (Cetrorelix) was used during ovarian stimulation in 32 patients… 
Highly Cited
1994
Highly Cited
1994
Sustained suppression of serum LH, FSH and testosterone and increase of high‐density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men
OBJECTIVE Recently we have shown that single dose injections of the new GnRH antagonist cetrorelix ([Ac‐o‐Nal(2)1, D‐Phe(4CI)2, D… 
1994
1994
Inhibitory effect of bombesin/gastrin‐releasing peptide antagonist RC‐3095 and luteinizing hormone—releasing hormone antagonist SB‐75 on the growth of MCF‐7 MIII human breast cancer xenografts in…
Background. The results of several clinical trials using various luteinizing hormone‐releasing hormone agonists for treatment of… 
1994
1994
Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women.
In contrast to gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists do not show any stimulatory effect on the… 
Review
1992
Review
1992
Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)